Cationic Lipid Scaffold for Low-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for delivering biologically active agents, such as mRNA and RNAi, face challenges in achieving optimal systemic and local delivery to specific organs and tumors, including high toxicity and inefficient delivery, especially outside the liver, and there is a need for formulations with improved physical characteristics and reduced toxicity.
Innovation Solution
Development of a cationic lipid scaffold with specific chemical structures that form compounds suitable for local delivery to tissues like the eye, ear, skin, lung, muscle, or subcutaneous cells, and for systemic delivery, which are designed to reduce toxicity and improve therapeutic index by incorporating degradable functionalities and optimized physical characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cationic lipids are used for delivering biologically active agents, then delivery capability is achieved, but toxicity increases and delivery efficiency to specific organs and tumors is insufficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by incorporating degradable functionalities (such as ester bonds or other hydrolyzable groups) into the lipid scaffold. This structural parameter change allows the lipids to break down into less toxic metabolites after delivering their cargo, thereby maintaining delivery efficacy while reducing systemic toxicity and improving the therapeutic index.
Solution Approach 2:
The invention designs composite lipid structures that combine the essential cationic head group for nucleic acid binding with degradable linkers and modified hydrocarbon chains. These composite structures maintain the ability to form stable complexes with biologically active agents while introducing metabolic pathways that reduce accumulation and toxicity in non-target tissues.
2Adaptability or versatility
If current cationic lipids are used for systemic delivery, then broad distribution is achieved, but delivery precision to specific organs and tumors is insufficient
Solution Approach 1:
The patent introduces functional groups or modifications at specific locations on the lipid molecule (such as the hydrocarbon chain or head group region) that provide targeted interactions with receptors or transport mechanisms in specific organs or tumor tissues. This local modification approach enables the lipid to maintain systemic circulation while exhibiting preferential accumulation or enhanced delivery to desired target sites.
3Reliability
If higher concentrations of biologically active agents are used to overcome membrane barriers, then delivery effectiveness is improved, but toxic side effects increase
Solution Approach 1:
The modified cationic lipid acts as an intermediary carrier that facilitates the transport of biologically active agents through cellular membranes. The lipid forms stable complexes with the agents, protects them from degradation, and enables their entry into cells at lower concentrations than would be required without the carrier, thereby reducing the agents' direct toxic effects while maintaining delivery effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new cationic lipid scaffold enhances delivery efficacy with lower toxicity, allowing for effective local and systemic delivery of biologically active agents, including RNA and DNA, to specific tissues and tumors while minimizing side effects.
Implementation Method 1
cationic lipids which interact with a biologically active agent at one part and interact with a membrane system at another part
Implementation Method 2
interact with a membrane system at another part
Data Source
AI summary
This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.